Climb Bio (CLYM) Price & Analysis

Compare

365 Followers

CLYM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $8.79

Previous CloseN/A

Volume51.97K

Average Volume (3M)323.09K

Market Cap

$97.98M

Enterprise Value-$15.28M

Total Cash (Recent Filing)$98.06M

Total Debt (Recent Filing)$474.00K

Price to Earnings (P/E)―

Beta0.76

Next Earnings

Aug 19, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding67,575,770

10 Day Avg. Volume200,598

30 Day Avg. Volume323,092

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.16

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.15

Forecast

1Y Price Target

$9.00

Price Target Upside520.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe company received FDA clearance for the trial, which was supported by compelling early data showing treatment with budo led to complete remission.

Pipeline DevelopmentCLYM plans to initiate multiple trials for budo in different indications, showing a strong pipeline development strategy.

Strategic PartnershipsCLYM has expanded their B-cell focused pipeline by in-licensing anti-APRIL antibody CLYM116 from Mabworks Biotech, with plans to develop the drug in IgA nephropathy.

Bears Say

Market CompetitionCLYM is viewed as a promising early entrant into the CD19-targeting space for autoimmune diseases, with validated clinical and commercial potential.

Climb Bio News

Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy’ Stocks

There’s a lot to say about the economy and markets today. Earnings season is well underway, with 317...

2d ago

WVE

CLYM

Climb Bio Appoints Cindy Driscoll as Finance VP

The latest announcement is out from Climb Bio ( ($CLYM) ). Climb Bio, Inc. has appointed Cindy Driscoll...

2M ago

CLYM

Climb Bio appoints Charles as CMO, Driscoll as SVP, Finance

Climb Bio (CLYM) announced the appointments of Edgar Charles, M.D., MSc as its Chief Medical Officer, CMO, and...

2M ago

BMY

CLYM

Climb Bio initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Climb Bio (CLYM) with an Outperform rating and $10 price target The company’s lead...

2M ago

CLYM

Climb Bio Elects New Board Members at Annual Meeting

An announcement from Climb Bio ( ($CLYM) ) is now available. On June 4, 2025, Climb Bio, Inc....

2M ago

CLYM

Climb Bio Appoints Interim CFO Amid Leadership Change

Climb Bio ( ($CLYM) ) has issued an update. On May 23, 2025, Climb Bio, Inc. announced the...

2M ago

CLYM

Climb Bio initiated with a Buy at BTIG

BTIG initiated coverage of Climb Bio (CLYM) with a Buy rating and $7 price target Climb’s budoprutug is...

2M ago

CLYM

Climb Bio Reports Increased Losses Amid Ongoing Development

Eliem Therapeutics, Inc. ( ($CLYM) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

CLYM

Climb Bio reports Q1 EPS (31c) vs (6c) last year

“2025 is a critical year of execution for Climb Bio (CLYM) and we continue to make excellent progress...

3M ago

CLYM

Climb Bio Expands Board with New Director Appointments

The latest update is out from Climb Bio ( ($CLYM) ). On March 27, 2025, Climb Bio, Inc....

4M ago

CLYM

Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board

Climb Bio (CLYM) announced the appointments of Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of...

4M ago

CLYM

SLDB

Climb Bio’s Strategic Advancements and Promising Pipeline Drive Buy Rating

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Climb Bio (CLYM – Research Report) on March...

4M ago

CLYM

Climb Bio Advances Clinical Trials and Expands Pipeline

Climb Bio, Inc. ( ($CLYM) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

CLYM

Climb Bio reports Q4 EPS (13c) vs (13c) last year

Cash, cash equivalents and marketable securities were $212.5M as of December 31 as compared to $106.8M as of...

4M ago

CLYM

CLYM FAQ

What was Climb Bio’s price range in the past 12 months?

Climb Bio lowest stock price was $1.05 and its highest was $8.79 in the past 12 months.

What is Climb Bio’s market cap?

Climb Bio’s market cap is $97.98M.

When is Climb Bio’s upcoming earnings report date?

Climb Bio’s upcoming earnings report date is Aug 19, 2025 which is in 16 days.

How were Climb Bio’s earnings last quarter?

Climb Bio released its earnings results on May 14, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.16.

Is Climb Bio overvalued?

According to Wall Street analysts Climb Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Climb Bio pay dividends?

Climb Bio does not currently pay dividends.

What is Climb Bio’s EPS estimate?

Climb Bio’s EPS estimate is -0.19.

How many shares outstanding does Climb Bio have?

Climb Bio has 67,575,770 shares outstanding.

What happened to Climb Bio’s price movement after its last earnings report?

Climb Bio reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -7.874%.

Which hedge fund is a major shareholder of Climb Bio?

Currently, no hedge funds are holding shares in CLYM

Climb Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-62.04%

Trailing 12-Months

Asset Growth

83.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Climb Bio

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Climb Bio (CLYM) Earnings & Revenues

CLYM Earnings Data >

CLYM Stock 12 Month Forecast

Average Price Target

$9.00

▲(520.69%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2022","6":"May<br/>2023","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.8584615384615384,2.5369230769230766,3.2153846153846155,3.8938461538461535,4.572307692307692,5.25076923076923,5.929230769230768,6.607692307692307,7.286153846153846,7.964615384615384,8.643076923076922,9.321538461538461,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.7815384615384615,2.3830769230769233,2.9846153846153847,3.586153846153846,4.187692307692307,4.78923076923077,5.390769230769231,5.992307692307692,6.593846153846154,7.195384615384615,7.796923076923077,8.39846153846154,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.6276923076923078,2.0753846153846154,2.523076923076923,2.970769230769231,3.418461538461538,3.8661538461538463,4.313846153846154,4.7615384615384615,5.2092307692307696,5.656923076923077,6.104615384615385,6.552307692307693,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.42,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >